Skip to main content
. 2020 Jul 28;10(47):28243–28266. doi: 10.1039/d0ra05434h

Therapeutics for COVID-19 based on existing drugs.

Drug candidate Target Classification Mechanism of action Reference
Chloroquine and hydroxychloroquine Endosome-ACE2 Antimalarial drug Prevent viral entry via inhibiting viral protein glycosylation and increasing endosomal pH 86, NCT01067417
Remdesivir, favipiravir, ribavirin, galidesiver RdRp Ebola, hepatitis C, Marburg virus Nucleoside analog enters into the viral RNA chain, causing premature termination 81, NCT04257656, NCT04319900
Arbidol Spike protein-ACE2 Influenza antiviral drug Prevents viral cell fusion with host cells 91, NCT04260594, NCT04255017, NCT04252885
Oseltamivir Exocytosis of new virus from host cells Influenza antiviral drug Prevents the secretion of neuraminidase from virus cells, which initiates the release of new virus into host cells 89, NCT04303299
Famotidine PLpro Antacid Inhibits viral PLpro activity 92
HHS Vulnerability Disclosure